Skip to main content
SpringerLink
Log in

Sexualsteroide und die Karzinogenese des Mammakarzinoms

  • Chapter
Management des MAMMAKARZINOMS

Part of the book series: Onkologie ((ONKAKTUELL))

  • 75 Accesses

Zusammenfassung

Epidemiologische Daten haben Dauer und Zeitraum der Einwirkung von Östrogenen auf das Brustdrüsengewebe mit der Entwicklung von Brustkrebs in Zusammenhang gebracht.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  • Adlercreutz H, Gorbach SL, Goldin BR, Woods MN, Dwyer JT, Hamalainen E (1994) Estrogen metabolism and excretion in Oriental and Caucasian women. J Natl Cancer Inst 86:1076–82

    Article  PubMed  CAS  Google Scholar 

  • Armstrong BK (1988) Oestrogen therapy after menopause -boon or bane? Med J Aust 148: 213–214

    PubMed  CAS  Google Scholar 

  • Barrett JC (1993) Mechanisms of multistep carcinogenesis and carcinogen risk assessment. Environ Health Perspect 100: 9–12

    Article  PubMed  CAS  Google Scholar 

  • Barrett JC, Tsutsui T (1996) Mechanisms of estrogen-associated carcinogenesis. In: Huff J, Boyd J, Barrett JC (eds): Cellular and molecular mechanisms of hormonal carcinogenesis: environmental influences. Wiley-Liss: 105–111

    Google Scholar 

  • Barrett JC, Wong A, McLachlan JA (1981) Diethylstilbestrol induces neoplastic transformation without measurable gene mutation at two loci. Science 212 (4501): 1402–1404

    Article  PubMed  CAS  Google Scholar 

  • Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C (1989) The risk of breast cancer after estrogen and estrogen-proge-stin replacement (see comments). N Engl J Med 321 (5): 293–297

    Article  PubMed  CAS  Google Scholar 

  • Bocchinfuso WP, Hively WP, Couse JF, Varmus HE, Korach KS (1999) A mouse mammary tumor virus-Wnt-1 transgene induces mammary gland hyperplasia and tumorigenesis in mice lacking estrogen receptor-alpha. Cancer Res 59 (8): 1869–1876

    PubMed  CAS  Google Scholar 

  • Bonnier P, Romain S, Giacalone PL, Laffargue F, Martin PM, Piana L (1995) Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 85:11–17

    Article  PubMed  CAS  Google Scholar 

  • Brewster WR, DiSaia PJ, Grosen EA, McGonigle KF, Kuykendall JL, Creasman WT (1999) An experience with estrogen replacement therapy in breast cancer survivors. Int J Fertil Womens Med 44 (4): 186–192

    PubMed  CAS  Google Scholar 

  • Cavalieri EL, Stack DE, Devanesan PD et al. (1997) Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci USA 94 (20): 10937–10942

    Article  PubMed  CAS  Google Scholar 

  • Cerhan JR, Kushi LH, Olson JE, Rich SS, Zheng W, Folsom AR, Sellers TA (2000) Twinship and risk of postmenopausal breast cancer. J Natl Cancer Inst 92 (3): 261–265

    Article  PubMed  CAS  Google Scholar 

  • Chetrite GS, Kloosterboer HJ, Philippe JC, Pasqualini JR (1999) Effect of Org OD14 (LIVIAL) and its metabolites on human estrogen sulphotransferase activity in the hormone-dependent MCFR-7 and T-47D, and the hormone-independent MDA-MB-231 breast cancer cell lines. Anticancer Res 19 (1A): 269–275

    PubMed  CAS  Google Scholar 

  • Clarke CL, Sutherland RL (1990) Progestin Regulation of Cellular Proliferation. Endocr Rev 11 (2): 96–125

    Article  Google Scholar 

  • Clarke CL, Sutherland RL (1993) Progestin Regulation of Cellular Proliferation: Update 1993. Endocr Rev 1 (1): 132–135

    Google Scholar 

  • Colditz GA, Egan KM, Stampfer MJ (1993) Hormone replacement therapy and risk of breast cancer: results from epidemiologic studies. Am J Obstet Gynecol 168:1473–1480

    PubMed  CAS  Google Scholar 

  • Colditz GA, Hankinson SE, Hunter DJ et al. (1995) The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. New Engl J Med 332 (24): 1589–1593

    Article  PubMed  CAS  Google Scholar 

  • Collaborative Group on Hormonal Factors in Breast Cancer (1997) Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer, [see comments] [published erratum appears in Lancet 1997 Nov 15; 350 (9089):1484]. Lancet 350 (9084): 1047–1059

    Article  Google Scholar 

  • Collaborative Group on Hormonal Factors in Breast Cancer (1996) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100239 women without breast cancer from 54 epidemiological studies. Lancet 347 (9017): 1713–1727

    Article  Google Scholar 

  • DiSaia PJ, Grosen EA, Odicino F, Cowan B, Pecorelli S, Wile AG, Creasman WT (1995) Replacement therapy for breast cancer survivors. A pilot study. Cancer 76 (10 Suppl):2075–2078

    Article  Google Scholar 

  • Dupont WD, Page DL (1991) Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 151: 67–72

    Article  PubMed  CAS  Google Scholar 

  • Dupont WD, Page DL, Rogers LW, Parl FF (1989) Influence of exogenous estrogens, proliferative breast disease, and other variables on breast cancer risk. Cancer 63:948–957

    Article  PubMed  CAS  Google Scholar 

  • Eden JA, Wren BG (1996) Hormone replacement therapy after breast cancer: a review. Cancer Treat Rev 22 (5): 335–343

    Article  PubMed  CAS  Google Scholar 

  • Ettinger B et al. (1999) Multiple Outcomes of Raloxifene Evaluation (MORE randomized trial). J Am Med Ass 281 (23): 2189–2197

    Article  Google Scholar 

  • Ewertz M (1988) Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 42: 832–838

    Article  PubMed  CAS  Google Scholar 

  • Folsom AR, Min PJ, Sellers TA, Hong C-P, Zheng W, Potter JD (1995) Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health 85 (8): 1128–1132

    Article  PubMed  CAS  Google Scholar 

  • Gajdos C, Tartter PI, Babinszki A (2000) Breast cancer diagnosed during hormone replacement therapy. Obstetrics and Gynecology 95 (4): 513–518

    Article  PubMed  CAS  Google Scholar 

  • Gemeinsame Stellungnahme der Deutschen Menopausenge-sellschaft, der European Menopause and Andropause Society, der Deutschen Gesellschaft für Senologie, der Deutschen Krebsgesellschaft u. a. (2000) Unterscheiden sich Gestagene hinsichtlich ihres Risikopotentials? Frauenarzt 41 (6): 714–718

    Google Scholar 

  • Grady D, Rubin SM, Petitti DB et al. (1992) Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Int Med 117:1016–1037

    Article  PubMed  CAS  Google Scholar 

  • Grodstein F, Stampfer MJ, Colditz GA (1997) Postmenopausal hormone therapy and mortality [see comments]. N Engl J Med 336 (25): 1769–1775

    Article  PubMed  CAS  Google Scholar 

  • Han X, Liehr JG (1994) DNA single-strand breaks in kidneys of Syrian hamsters treated with steroidal estrogens: hormone-induced free radical damage preceding renal malignancy. Carcinogenesis 15 (5): 997–1000

    Article  PubMed  CAS  Google Scholar 

  • Harris RE, Namboodiri KK, Farrar WB, Solano SM, Wynder EL (1996) Hormone replacement therapy and breast cancer risk. JAMA 275:1158, discussion 1159–1160

    Google Scholar 

  • Henderson BE, Paganini-Hill A, Ross RK (1991) Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 151:75–78

    Article  PubMed  CAS  Google Scholar 

  • Hodgson AV, Ayala-Torres, S, Thompson, EB, Liehr JG (1998) Estrogen-induced microsatellite DNA alterations are associated with Syrian hamster kidney tumorigenesis. Carcinogenesis 19 (12): 2169–2172

    Article  PubMed  CAS  Google Scholar 

  • Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ (1999) Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 84 (12): 4559–4565

    Article  PubMed  CAS  Google Scholar 

  • Hunt K, Vessey M, McPershon K (1990) Mortality in a cohort of long-term users of hormone replacement therapy: an update analysis. Br J Obstet Gynecol 97:1080–1086

    Article  CAS  Google Scholar 

  • Kandouz M Lombet A, Perrot JY et al. (1999) Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells. J Steroid Biochem Molec Biol 69 (1–6): 463–471

    Article  PubMed  CAS  Google Scholar 

  • Kloosterboer HJ, Schoonen WG, Deckers GH, Klijn JG (1994) Effects of progestagens and Org OD14 in vitro and in vivo tumor models. J Steroid Biochem Molec Biol 49 (4–6): 311–318

    Article  PubMed  CAS  Google Scholar 

  • Kroman N, Jensen MB, Melbye M, Wohlfahrt J, Mouridsen HT (1997) Should women be advised against pregnancy after breast-cancer treatment? Lancet 350 (9074): 319–322

    Article  PubMed  CAS  Google Scholar 

  • Kurebayashi J, Otsuki T, Kunisue H, Tanaka K, Yamamoto S, Sonoo H (2000) Expression levels of estrogen receptor-alpha, estrogen receptor-beta, coactivators, and corepressors in breast cancer. Clin Cancer Res 6 (2): 512–518

    PubMed  CAS  Google Scholar 

  • Lange CA, Richer JK, Horwitz KB (1999) Hypothesis: Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol 13 (6): 829–836

    Article  PubMed  CAS  Google Scholar 

  • LaVecchia C et al. (1995) Hormone replacement treatment and breast cancer risk: a cooperative Italian study. Br J Cancer 72: 244–248

    Article  PubMed  Google Scholar 

  • Li JJ, Hou X, Banerjee SK, Liao DZ, Maggouta F, Norris JS, Li SA (1999) Overexpression and amplification of c-myc in the Syrian hamster kidney during estrogen carcinogenesis: a probable critical role in neoplastic transformation. Cancer Res 59 (10): 2340–2346

    PubMed  CAS  Google Scholar 

  • Liehr JG (2000) Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 21 (1): 40–54

    Article  PubMed  CAS  Google Scholar 

  • Liehr JG, Avitts TA, Randerath E, Randerath K (1986a) Estrogen-induced endogenous DNA adduction: possible mechanism of hormonal cancer. Proc Natl Acad Sci USA 83 (14): 5301–5305

    Article  PubMed  CAS  Google Scholar 

  • Liehr JG, Stancel GM, Chorich LP, Bousfield GR, Ulubelen AA (1986b) Hormonal carcinogenesis: separation of estrogenicity from carcinogenicity. Chem Biol Interact 59 (2): 173–184

    Article  PubMed  CAS  Google Scholar 

  • Liehr JG, Ricci MJ (1996) 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc Natl Acad Sci USA 93 (8): 3294–3296

    Article  PubMed  CAS  Google Scholar 

  • Longacre TA, Bartow SA (1986) A correlative morphologic study of human breast and endometrium in the menstrual cycle. Am J Surg Patholio (6): 382–393

    Google Scholar 

  • Magnusson C, Baron JA, Correia, N, Bergstrom R, Adami HO Persson I (1999) Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. Int J Cancer 81 (3): 339–344

    Article  PubMed  CAS  Google Scholar 

  • Newcomb PA, Longnecker MP, Storer BE (1995) Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol 142: 788–795

    PubMed  CAS  Google Scholar 

  • O’Neill JS, Elton RA, Miller WR (1988) Aromatase activity in adipose tissue from breast quadrants: a link with tumour site. Br Med J Clin Res Ed 296 (6624): 741–743

    Article  PubMed  Google Scholar 

  • Osborne CK (1998) Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 51 (3): 227–238

    Article  PubMed  CAS  Google Scholar 

  • Osborne CK, Bradlow HL, Wong GY, Telang NT (1993) Upregulation of estradiol C16 alpha-hydroxilation in human breast tissue: a potential biomarker of breast cancer risk. J Natl Cancer Inst 85 (23): 1917–1920

    Article  PubMed  CAS  Google Scholar 

  • Persson I, Yuen J, Bergvist L, Schairer C (1996) Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy — long-term follow-up of a Swedish cohort. Int J Cancer 67:327–332

    Article  PubMed  CAS  Google Scholar 

  • Potischman N, Troisi R (1999) In-utero and early life exposures in relation to risk of breast cancer. Cancer Causes Control 10 (6): 561–573

    Article  PubMed  CAS  Google Scholar 

  • Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE (1990) Increased cell division as a cause of human cancer. Cancer Res 50:7415–7421

    PubMed  CAS  Google Scholar 

  • Richer JK, Lange CA, Manning NG, Owen G, Powell R, Horwitz, KB (1998) Convergence of progesterone with growth factor and cytokine signaling in breast cancer. Progesterone receptors regulate signal transducers and activators of transcription expression and activity. J Biol Chem 273 (47): 31317–31326

    Article  PubMed  CAS  Google Scholar 

  • Rosenberg L, Palmer JR, Rao RS et al. (1996) Case-control study of oral contraceptive use and risk of breast cancer. Am J Epidemiol 143 (1): 25–37

    Article  PubMed  CAS  Google Scholar 

  • Ross RK, Paganini Hill A, Wan PC, Pike MC (2000) Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin. Journal of the National Cancer Institute 92 (4): 328–332

    Article  PubMed  CAS  Google Scholar 

  • Russo J, Russo IH (1995) The etiopathogenesis of breast cancer prevention. Cancer Lett 90 (1): 81–89

    Article  PubMed  CAS  Google Scholar 

  • Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R (2000) Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA — Journal of the American Medical Association 283 (4): 485–491

    Article  CAS  Google Scholar 

  • Schneider J, Kinne D, Fracchia A, Pierce V, Anderson KE, Brad-low HL, Fishman L (1982) Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc Natl Acad Sci 79 (9): 3047–3051

    Article  PubMed  CAS  Google Scholar 

  • Sillero-Arenas M, Delgado-Rodriguez M, Rodigues-Canteras R, Bueno-Cavanillas A, Galvez-Vargas R (1992) Menopausal hormone replacement therapy and breast cancer: a metaanalysis. Obstet Gynecol 79: 286–294

    PubMed  CAS  Google Scholar 

  • Simpson ER, Merrill JC, Hollub AJ, Graham-Lorence S, Mendelson CR (1989) Regulation of estrogen biosynthesis by human adipose cells. Endocr Rev 10 (2): 136–148

    Article  PubMed  CAS  Google Scholar 

  • Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA (1995) Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 274:137–142

    Article  PubMed  CAS  Google Scholar 

  • Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, Berkelman RL (1991) A metaanalysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 265 (15): 1985–1990

    Article  PubMed  CAS  Google Scholar 

  • Tsutsui T, Suzuki N, Fukuda S, Sato M, Maizumi H, McLachlan JA, Barrett JC (1987) 17beta-Estradiol-induced cell transformation and aneuploidy of Syrian hamster embryo cells in culture. Carcinogenesis 8 (11): 1715–1719

    Article  PubMed  CAS  Google Scholar 

  • Ursin G, London S, Stanczyk FZ, Gentzschein E, Paganini-Hill A, Ross RK, Pike MC (1999) Urinary 2-hydroxyestro-ne/16alpha-hydroxyestrone ratio and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 91 (12): 1067–1072

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. K. Krauß
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Universitätsfrauenklinik, Universität Ulm, Prittwitzstraße 43, D-89075, Ulm, Deutschland

    Rolf Kreienberg  & Tanja Volm  & 

  2. Städt. Kliniken Frankfurt-Höchst Akademisches Lehrkrankenhaus, Universität Frankfurt, Frauenklinik, Gotenstraße 6-8, D-65929, Frankfurt, Deutschland

    Volker Möbus

  3. Untere Kippstraße 21, D-69198, Schriesheim, Deutschland

    Dieter Alt

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Krauß, K. (2002). Sexualsteroide und die Karzinogenese des Mammakarzinoms. In: Kreienberg, R., Volm, T., Möbus, V., Alt, D. (eds) Management des MAMMAKARZINOMS. Onkologie Aktuell . Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-08460-1_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-08460-1_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-08461-8

  • Online ISBN: 978-3-662-08460-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation